Skip to content

K-Stock Briefing

https://kstockbriefing.com

  • About Us
  • Weekly News
  • IR Room
  • RESEARCH
    • Semiconductors
  • Disclosures
    • Semiconductors
    • Energy
    • Bio & Healthcare
    • Defense
    • Shipbuilding
    • Automotive
  • Toggle search form
  • [Disclosure] Hyundai Motor (005380) – Investor Relations(IR) Schedule / 2026-06-18 Disclosures
  • [Research] Samsung Electronics (005930) – DS Investment & Securities | DRAM ASP · LTA Visibility · Profit Growth / 2026-07-30 RESEARCH
  • [Disclosure] Samsung Electronics (005930) – (Correction) Provisional Performance Results (Consolidated) / 2026-01-29 Semiconductors
  • [Disclosure] Hanwha Aerospace (012450) – Paid-in Capital Increase Decision of Subsidiary / 2025-03-17 Disclosures
  • [Disclosure] ALTEOGEN (196170) – Clarification on Rumors or News Reports (Unconfirmed) / 2024-11-21 Disclosures
  • [Disclosure] Hanmi Semiconductor (042700) – Investor Relations (IR) Presentation / 2025-02-14 Semiconductors
  • [Disclosure] Hanmi Semiconductor (042700) – Investor Relations (IR) Presentation / 2024-07-12 Semiconductors
  • [Disclosure] SK Hynix (000660 / SKHY) – Investor Relations (IR) Event (Informational Disclosure) / 2024-10-10 Semiconductors

[Disclosure] ISU PETASYS (007660) – Results of Annual General Meeting of Shareholders / 2024-03-29

Posted on March 29, 2024August 1, 2026 By K-STOCK Editor

Fact Source: Financial Supervisory Service DART

💡 3-Second Summary

ISU PETASYS held its 52nd Annual General Meeting of Shareholders, approving a cash dividend of KRW 100 per common share and passing all agenda items as originally submitted, including the appointment of an executive director and a standing statutory auditor.

📊 [Key Disclosure Details & Financial Summary]

  1. FY2023 Financial Statements Overview (Consolidated / Separate):
  • Consolidated: Total Assets KRW 626.436B, Revenue KRW 675.333B, Operating Profit KRW 62.169B, Net Income KRW 47.723B (EPS: KRW 755)
  • Separate: Total Assets KRW 543.837B, Revenue KRW 579.045B, Operating Profit KRW 50.217B, Net Income KRW 36.437B (EPS: KRW 576)
  • Audit Opinion: Unqualified (both Consolidated and Separate)
  1. Dividend Details:
  • Dividend Type: Year-end Cash Dividend
  • Dividend per Share: KRW 100 per Common Share
  • Total Dividend Amount: KRW 6,324,641,900 (approx. KRW 6.32B)
  • Dividend Yield: Common Shares 0.3%
  1. Executive Appointments:
  • Executive Director (New): Won-ho Yang (3-year term, Head of Management Headquarters at ISU PETASYS)
  • Statutory Auditor (New, Full-time): Sook Kim (3-year term, Head of Pension & Trust at KDB)
  • Post-AGM Board/Auditor Composition: 4 Directors in total (1 Outside Director, 25% ratio), 1 Full-time Statutory Auditor
  1. Voting Results on Agenda Items:
  • Agenda 1: Changed to a reporting item per unqualified audit opinion, unanimous auditor consent, and board resolution
  • Agenda 2: Appointment of Executive Director (1 candidate) -> Approved as submitted
  • Agenda 3: Appointment of Statutory Auditor -> Approved as submitted
  • Agenda 4: Partial Amendment to Articles of Incorporation -> Approved as submitted
  • Agenda 5: Approval of Director Remuneration Limit -> Approved as submitted
  • Agenda 6: Approval of Auditor Remuneration Limit -> Approved as submitted
  1. Date of AGM: March 29, 2024

📝 Editor’s Comment (Key Follow-up Checkpoint)

📌 Approval of AGM Resolutions and Post-Meeting Governance Structure

The company confirmed its FY2023 financial results, cash dividends, and passed all submitted agenda items at the 52nd AGM. Tracking the operational governance under the newly appointed executive management and updated Articles of Incorporation is important for ongoing evaluation. Relevant details can be tracked through upcoming quarterly and annual financial reports following the AGM.

📢 Disclaimer & Source Notice

Source: This content has been newly structured and created based on official filing data from the Financial Supervisory Service DART system.

Investment Risk Warning: This content is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific securities. All investment decisions and financial liabilities rest entirely with the investor.

Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.

Search by
Company Name or Stock Ticker.
Semiconductors, Disclosures

Post navigation

Previous Post: [Disclosure] Hana Micron (067310) – Results of Annual General Meeting of Shareholders / 2024-03-28
Next Post: [Disclosure] HPSP (403870) – Change of Head Office Location / 2024-03-29

Related Posts

  • [Disclosure] LEENO Industrial (058470) – Modification Listing (Change in Par Value) (Stock Split) / 2025-04-24 Disclosures
  • [Disclosure] Hyundai Motor (005380) – (Corrected) Decision on Acquisition of Shares and Equity Securities in Other Corporations / 2025-08-07 Disclosures
  • [Disclosure] Samsung Electronics (005930) – (Correction) Resolution on Convening of General Meeting of Shareholders / 2026-02-25 Semiconductors
  • [Disclosure] Hanmi Semiconductor (042700) – Provisional Operating Results (Consolidated) / 2025-10-31 Semiconductors
  • [Disclosure] LEENO Industrial (058470) – New Facility Investment / 2024-11-08 Semiconductors
  • [Disclosure] KEPCO (015760 / KEP) – Resolution on Convening of General Shareholders Meeting / 2025-02-28 Disclosures
  • [Disclosure] Hanwha Ocean (042660) – Decision on Acquisition of Shares and Equity Securities of Other Corporation / 2025-02-18 Disclosures
  • [Disclosure] Jeju Semiconductor(080220) – (Correction) Resolution on Convening of Extraordinary General Meeting of Shareholders / 2026-07-07 Disclosures
  • [Disclosure] Celltrion (068270) – Approval of Phase 3 Clinical Trial Plan for CT-P55 (Cosentyx Biosimilar) in the U.S. / 2024-08-14 Disclosures
  • [Disclosure] Hanwha Systems (272210) – Sales / Supply Contract / 2025-04-30 Disclosures
  • [Disclosure] Hanmi Semiconductor (042700) – Investor Relations (IR) Holding / 2024-05-10 Semiconductors
  • [Disclosure] Celltrion (068270) – Approval of Phase 3 Clinical Trial Plan (Part 2) in Europe for CT-P44 (Darzalex Biosimilar) / 2025-09-01 Disclosures
  • [Disclosure] KEPCO (015760 / KEP) – Change in Revenue or Profit/Loss Structure Notice / 2026-02-26 Disclosures
  • [Disclosure] Celltrion (068270) – Provisional Sales Results (Consolidated Financial Statements) / 2024-05-09 Bio & Healthcare

Copyright © 2026 K-Stock Briefing.

Powered by PressBook News Dark theme